You are here: Industry Insights > ARCA

News List

ARCA Biopharma Completes Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as Treatment for Patients Hospitalized with COVID-19 AmericanPharmaceuticalReview
December 03, 2021
ARCA biopharma, Inc. announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. 160 patients were enrolled at clinical investigative...
Potential Treatment from ARCA for COVID-19 Receives Fast Track Designation americanpharmaceuticalreview
December 09, 2020
ARCA biopharma announced the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19.
ARCA Announces IND Application Approval for Potential COVID-19 Treatment americanpharmaceuticalreview
October 14, 2020
ARCA biopharma announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for AB201 (rNAPc2) as a potential treatment for patients hospitalized with COVID-19.
ARCA gets FDA approval of IND for Covid-19 drug candidate AB201 pharmaceutical-business-review
October 10, 2020
ARCA biopharma said that its investigational new drug (IND) application for AB201 (rNAPc2) as a potential treatment for patients hospitalised with Covid-19 has been approved by the US Food and Drug Administration (FDA).
ARCA Submits IND Application for AB201 as Potential COVID-19 Treatment americanpharmaceuticalreview
September 27, 2020
ARCA biopharma has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with ...
ARCA Submits IND for AB201 in COVID-19 contractpharma
September 22, 2020
AB201, a Phase IIb-ready recombinant protein aims to address the pathologies caused by viral infections from multiple aspects.
ARCA Announces AB201 Development Program for COVID-19 Associated Coagulopathy americanpharmaceuticalreview
June 04, 2020
ARCA biopharma announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment for COVID-19 associated coagulopathy (CAC) and the related inflammatory response.